FDAnews Drug Daily Bulletin

Biogen Touts MS Drug as Cost Effective

April 17, 2007
A A

Drug maker Biogen Idec Inc. said Friday a one-year study of its multiple sclerosis drug Avonex shows it is more cost-effective than similar treatments.
BusinessWeek